Data from medical records of 144 COVID-19 patients who completed inpatient treatment, as well as subsequent questionnaires using a modified questionnaire, were analyzed. The relationship between the level of physical activity, performance, and quality of life (before and after treatment), age, frequency of exercise therapy at the hospital stage, the presence of stool disorders, and episodes of increased blood pressure after treatment with the course of the disease were evaluated. Patients were divided into a control and experimental group depending on the initial subjective level of performance. The moderate form prevailed (69,44%). The mild form is typical for younger patients, patients older than 50 years make up 62,49% of the total number of cases of severe course. Patients who had a severe form of the disease noted the quality of life and performance before the disease at a lower level, in contrast to those who had a medium and light form. Initially leading a more active lifestyle, patients with initially higher performance and quality of life who performed exercise therapy at the hospital stage (with mild and moderate forms) have a more favorable course of the disease (reducing the time of hospitalization, early recovery of performance, reducing the number of CT scans). The initial higher physical activity contributes to a more favorable course of the disease. The initial higher physical activity contributes to a more favorable course of the disease. It is necessary to raise public awareness of the benefits of regular physical activity and its connection with the course of the disease, especially among the elderly, as well as to introduce exercise therapy at all stages of treatment.

Highly virulent virus SARS-CoV-2 first came public in Wuhan (China) and now spread all over the globe leading to disease of more than 14,5 mln of people and took already more than 600.000 lives. Main criteria defining severity of COVID-19 clinical course are age, respiratory failure and necessity of mechanical ventilation. According to actual published data the mortality of patients undergoing mechanical ventilation after respiratory failure due to SARS-CoV-2 pneumonitis riches 76,4% in 18-65 age group and 97,2% in 65+ age group [1]. At this moment the main life-saving method under threat of decompensated respiratory failure is extracorporeal membrane oxygenation (ECMO, «artificial lung») meaning direct blood oxygenation bypassing inflamed lung tissue. This method is invasive, expensive and accessible only in specialized top medical centers. At the moment China, USA, Germany, France, Israel initiated clinical and scientific trials of less invasive methods of COVID-19 patients oxygen treatment in cases of complicated clinical course. One of them is hyperbaric oxygen therapy (HBOT) [2]. HBOT is well-known and recognized method of treatment of chronic non-healing wounds, diabetic wounds, complications of radiation therapy, strokes and cerebral trauma consequences, decompression disease and many others [3]. Use of HBOT in viral pneumonitis patients treatment is based on immutable physical laws and knowledge of clinical response for hyperbaric and hyperoxic environment. In this article arguments are brought to substantiate the use of hyperbaric oxygen therapy in SARS-CoV-2 viral pneumonitis treatment and first comparative experience of salutary clinical use of HBOT in China in treatment of severe respiratory complicated cases of new coronavirus infection COVID-19.

Currently, there is no cure for pediatric diffuse brain stem (BS) tumors. Radiotherapy, including proton therapy, is an important component of combination treatment for this cancer, especially in children with a complicated medical history. The article addresses the issues of therapy for pediatric BS tumors and reports the use of proton re-irradiation in a 9-year-old boy with unverified diffuse BS tumor. Proton re-irradiation is an effective treatment option that can sustain and improve the quality of life and prolong survival in children with diffuse BS tumors.